Obstructive Sleep Apnea: CPAP Under Pressure As New Market Segments Awaken
An estimated 15 million Americans have obstructive sleep apnea severe enough to warrant treatment, but this field has been chronically underserved by traditional continuous positive airway pressure systems that are inconvenient and uncomfortable to use. To address this problem, CPAP manufacturers are making design improvements to optimize comfort and compliance; at the same time, promising new technologies are emerging – including neurostimulation devices for OSA – that could help reshape the future management of this often overlooked, but serious disorder.
You may also be interested in...
Largest Sleep Apnea Trial Backs CPAP For Improving QoL, Not For Lowering Secondary Cardio Events
In the largest sleep apnea study ever conducted, continuous positive airway pressure (CPAP) did not appear to lower the risk of cardiovascular adverse events including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina in patients with obstructive sleep apnea and known cardiovascular disease. However, patients in the trial only used CPAP a few hours a night, on average, indicating that an easier-to-use version of CPAP might yield better outcomes.
Digital Health Pushing Telemedicine To Center Stage
Remote monitoring is proving to be the driving force in the industry’s quest to reduce costs by keeping patients out of hospitals, and telemedicine is positioned to become a major part of that scheme. However, telemedicine has a number of components and players, and while the market offers opportunities, it could also prove to be somewhat disruptive to companies and products that do not fit in the envisioned landscape.
Regulatory Briefs: HHS Agenda; Cardiopulmonary Blood Pump Reclassification; FDA Meetings
HHS issued a semiannual report detailing the regulatory agenda for FDA in 2014. FDA reclassifies cardiopulmonary bypass blood pumps. More regulatory news.